Cellumen announced this week that it will spin out its personalized medicine unit into a separate entity to be called Cernostics Pathology. The new company will provide digital imaging pathology and tissue-based diagnostic products and services.
 
A Cellumen official told Cell-Based Assay News that Cernostics will build on Cellumen’s current collaborations, including its partnership with the Mayo Clinic and Foundation, to develop an advanced breast cancer diagnostic and theranostic test.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.